MX2017008189A - Composicion farmceutica que comprende plasminogeno y usos de este. - Google Patents

Composicion farmceutica que comprende plasminogeno y usos de este.

Info

Publication number
MX2017008189A
MX2017008189A MX2017008189A MX2017008189A MX2017008189A MX 2017008189 A MX2017008189 A MX 2017008189A MX 2017008189 A MX2017008189 A MX 2017008189A MX 2017008189 A MX2017008189 A MX 2017008189A MX 2017008189 A MX2017008189 A MX 2017008189A
Authority
MX
Mexico
Prior art keywords
plasminogen
pharmaceutical composition
contemplated
pharmaceutical compositions
particles
Prior art date
Application number
MX2017008189A
Other languages
English (en)
Inventor
Yu Betty
Robitaille Martin
Blackman Davida
Plum Stacy
Garzon-Rodriguez William
Original Assignee
Prometic Bio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Bio Therapeutics Inc filed Critical Prometic Bio Therapeutics Inc
Publication of MX2017008189A publication Critical patent/MX2017008189A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describe una composición farmacéutica que comprende plasminógeno o una variante biológicamente activa de este. En una modalidad, la composición comprende un modificador de tonicidad, un agente espesante y un agente estabilizante y tiene un pH de alrededor de 3,0 a alrededor de 10,0. En otra modalidad, la composición contiene una cantidad de partículas en suspensión igual o mayor que 10 µm que es menor que 6000 partículas cada 100 ml, y preferentemente menor que 2000 partículas cada 100 ml. Se contemplan los usos de estas composiciones como un medicamento. También se contemplan varios usos terapéuticos de estas composiciones farmacéuticas.
MX2017008189A 2014-12-19 2015-12-18 Composicion farmceutica que comprende plasminogeno y usos de este. MX2017008189A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094556P 2014-12-19 2014-12-19
PCT/CA2015/000606 WO2016095013A1 (en) 2014-12-19 2015-12-18 Pharmaceutical composition comprising plasminogen and uses thereof

Publications (1)

Publication Number Publication Date
MX2017008189A true MX2017008189A (es) 2018-03-23

Family

ID=56125498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008189A MX2017008189A (es) 2014-12-19 2015-12-18 Composicion farmceutica que comprende plasminogeno y usos de este.

Country Status (21)

Country Link
US (3) US10441639B2 (es)
EP (1) EP3233111A4 (es)
JP (2) JP6805162B2 (es)
KR (1) KR20170096178A (es)
CN (1) CN107249622B (es)
AR (1) AR103215A1 (es)
AU (1) AU2015367185B2 (es)
BR (1) BR112017012972A2 (es)
CA (1) CA2971359C (es)
CL (1) CL2017001605A1 (es)
CO (1) CO2017007137A2 (es)
IL (1) IL252967B (es)
MX (1) MX2017008189A (es)
MY (1) MY202111A (es)
PH (1) PH12017501118B1 (es)
RU (1) RU2711989C2 (es)
SG (1) SG11201704839RA (es)
TW (1) TWI705822B (es)
UA (1) UA123496C2 (es)
UY (1) UY36467A (es)
WO (1) WO2016095013A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
CA3008691A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Method for preventing or treating diabetic retinopathy
DK3391902T3 (da) 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
WO2018107687A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗高脂血症的方法
JP7313058B2 (ja) 2016-12-15 2023-07-24 タレンゲン インターナショナル リミテッド 組織器官の繊維化を予防及び治療するための方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
CN117460823A (zh) 2021-06-08 2024-01-26 先觉药业咨询公司 从血浆级分中分离纤溶酶原的方法
CN114191385B (zh) * 2021-12-22 2023-06-30 天士力生物医药股份有限公司 一种重组人尿激酶原注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE3119157A1 (de) * 1981-05-14 1982-12-09 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von und danach hergestelltes plasminogen
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
US5290764A (en) 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
JPH06211691A (ja) 1993-01-11 1994-08-02 Green Cross Corp:The プラスミノゲン乾燥製剤
JP2005272403A (ja) 2004-03-25 2005-10-06 Nihon Pharmaceutical Co Ltd プラスミノーゲン含有溶液の処理方法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070134231A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20100144622A1 (en) * 2006-09-29 2010-06-10 Xinli Lin Methods for production of recombinant plasminogen and plasmin polypeptides
CN102482338B (zh) * 2009-07-10 2016-09-28 斯路姆基因公司 纤溶酶原和纤溶酶的变体
EP2561070B1 (en) * 2010-04-20 2015-06-03 Octapharma AG New stabilizing agent for pharmaceutical proteins
TW201213342A (en) * 2010-09-17 2012-04-01 Baxter Int Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH
CN103764163A (zh) * 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体

Also Published As

Publication number Publication date
US20170360902A1 (en) 2017-12-21
CN107249622A (zh) 2017-10-13
UY36467A (es) 2016-07-29
PH12017501118A1 (en) 2017-11-27
RU2017125931A3 (es) 2019-07-24
CA2971359A1 (en) 2016-06-23
JP6805162B2 (ja) 2020-12-23
PH12017501118B1 (en) 2017-11-27
JP2018505209A (ja) 2018-02-22
IL252967A0 (en) 2017-08-31
US10441639B2 (en) 2019-10-15
RU2017125931A (ru) 2019-01-21
CL2017001605A1 (es) 2018-02-02
TWI705822B (zh) 2020-10-01
CO2017007137A2 (es) 2017-09-29
JP2021059549A (ja) 2021-04-15
MY202111A (en) 2024-04-04
AU2015367185B2 (en) 2021-05-27
CN107249622B (zh) 2021-08-03
US10898553B2 (en) 2021-01-26
RU2711989C2 (ru) 2020-01-23
JP7150804B2 (ja) 2022-10-11
EP3233111A1 (en) 2017-10-25
US20210106657A1 (en) 2021-04-15
KR20170096178A (ko) 2017-08-23
WO2016095013A1 (en) 2016-06-23
IL252967B (en) 2020-01-30
BR112017012972A2 (pt) 2018-02-27
US20200023043A1 (en) 2020-01-23
EP3233111A4 (en) 2018-06-27
TW201625294A (zh) 2016-07-16
AU2015367185A1 (en) 2017-08-10
CA2971359C (en) 2024-04-02
AR103215A1 (es) 2017-04-26
WO2016095013A8 (en) 2017-07-06
US11633462B2 (en) 2023-04-25
UA123496C2 (uk) 2021-04-14
SG11201704839RA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
PH12017501118B1 (en) Pharmaceutical composition comprising plasminogen and uses thereof
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
WO2014145485A3 (en) Map kinase modulators and uses thereof
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
MX2016013575A (es) Composicion para prevenir o tratar enfermedades del higado graso.
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
GEP201706717B (en) Fibrinolytic compositions comprising bromelain and nattokinase for prevention and treatment of phlebothrombtic states
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
WO2014115084A3 (en) Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof
MX2016005720A (es) Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
MX2018008443A (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada.